CSAF-AW study

  • Research type

    Research Study

  • Full title

    A non-invasive, prolonged surveillance strategy using Apple watch for atrial fibrillation detection in cryptogenic stroke

  • IRAS ID

    284826

  • Contact name

    Richard Schilling

  • Contact email

    richard.schilling@nhs.net

  • Sponsor organisation

    Barts Health NHS Trust

  • Clinicaltrials.gov Identifier

    NCT05007847

  • Duration of Study in the UK

    2 years, 0 months, 1 days

  • Research summary

    No cause for stroke is found in up to 30% of cases despite extensive investigations. These are called cryptogenic strokes (CS). 1 in 4 stroke survivors will suffer another in 5 years and this is a leading cause of fear and anxiety. A common reason for CS is an undetected heart rhythm disorder called atrial fibrillation (AF). AF occurs intermittently, so it may not be detected during the mandated 24-96 hours of rhythm monitoring that is performed as part of the standard post-stroke investigation strategy.

    A randomised controlled study in 2014 showed that this standard monitoring strategy picks up AF in 2% of CS patients, but continuous monitoring for 12 months using an implantable recording device can pick up AF in 13% of patients. This suggests the standard strategy may miss AF in a proportion of CS patients and thus also the opportunity to mitigate against further strokes with anticoagulation therapy. Long-term monitoring has traditionally required a minimally-invasive surgical procedure to implant a recording device under the skin at a specialist centre. A specifically trained team is also required to interpret the large number of recordings this strategy yields.

    The Apple Watch (AW) is a wristwatch able to monitor a wearer’s heart rate and rhythm regularity and facilitates real-time, single-lead ECG recordings. This over-the-counter, non-invasive device has demonstrated feasibility and has a CE Mark for detecting AF. It may offer a potential non-invasive alternative long-term rhythm surveillance strategy to diagnose AF in these patients.

    We propose a study in which CS patients will be randomised in a 1:1 ratio to receive additional AW monitoring on top of standard care versus standard care alone. We shall then explore the incidence of AF in the two groups at 1 year and how it impacts on clinical outcomes too.

  • REC name

    West Midlands - Solihull Research Ethics Committee

  • REC reference

    21/WM/0230

  • Date of REC Opinion

    10 Nov 2021

  • REC opinion

    Further Information Favourable Opinion